Association of polycystic ovaries with the use of valproic acid in Jordanian epileptic patients

Clinical Drug Investigation

Volumn 23, Issue 8, 2003, Pages 527-532

  Otoom, S ^a   Nusier, M ^a   Hasan, M ^a   Hadidi, H ^a   Samawi, R ^b   Younes, A M ^b   Darweesh, M ^c   Boulatova, N R ^d  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b Al Basheer Hospital   (Jordan)

^c Princess Basma Teaching Hospital   (Jordan)

^d UNIVERSITY OF JORDAN   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; VALPROIC ACID;

ADULT; AMENORRHEA; ANTICONVULSANT THERAPY; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HIRSUTISM; HUMAN; HYPERANDROGENISM; JORDAN; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY; WEIGHT GAIN;

EID: 0042883734     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323080-00005     Document Type: Article

References (25)

1. Chapman A, Keane PE, Meldrum BS, et al. Mechanism of action of valproate. Prog Neurobiol 1982; 19: 315-44
2. Cotariu D, Zaidman JL, Evans S. Neurophysiological and biochemical changes evoked by valproic acid in the central nervous system. Prog Neurobiol 1990; 34: 343-11
3. Giroud M, Dumas R. Treatment of status epilepticus by sodium valproate. Neurophysiol Clin 1988; 18: 21-32
4. Wilbur R, Kulik FA. Anticonvulsant drugs in alcohol withdrawal: use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants. Am J Hosp Pharm 1981; 38: 1138-5
5. Miyazaki C, Matsuyama K, Ichikawa M, et al. Effect of sodium valproate (VPA) on cerebral amino acids: mechanism of gamma-aminobutyric acid (GABA) elevation and possible causal relation of VPA-induced encephalopathy and glutamine level. Chem Pharm Bull 1988; 36: 3589-5
6. Macdonald RL, Kelly KM. Mechanism of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia 1994; 35 Suppl. 4: 41-9
7. Triggs WJ, Bohan TP, Lin SN, et al. Valproate-induced coma with ketosis and carnitine insufficiency. Arch Neurol 1990; 47 (10): 1131-3
8. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334 (3): 168-75
9. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329 (19): 1383-8
10. Isojarvi JI, Laatikainen TJ, Knip M. et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996 May: 39 (5): 579-12
11. Taubol E, Isojarvi JI, Habro HF, et al. Long-term valproate treatment induces changes in ovarian morphology and serum sex steroid hormone levels in female Wistar rats. Seizure 1999 Dec; 8 (8): 490-3
12. Chappell KA, Markowitz JS, Jackson CW. Is valproate pharmacotherapy associated with polycystic ovaries? Ann Pharmacother 1999 Nov; 33 (11): 1211-6
13. Isojarvi JI, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Arch Neurol 2000 Jul; 57 (7): 1064-8
14. Herzog AG. Polycystic ovarian syndrome in women with epilepsy: epileptic or iatrogenic? Ann Neurol 1996; 39: 559-1
15. Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 341-5
16. Legro RS, Driscoll D, Strauss JF, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998; 95: 14956-4
17. Legro RS. Polycystic ovary syndrome: phenotype to genotype. Endocrinol Metab Clin North Am 1999; 28 (2): 379-17
18. Herzog AG. Reproductive endocrine considerations and hormonal therapy for men with epilepsy. Epilepsia 1991; 132 Suppl. 6: 34-7
19. Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992; 71 (8): 599-5
20. Wild RA, Alaupovic P, Givens JR, et al. Lipoprotein abnormalities in hirsute women. II: compensatory responses of insulin resistance and dehydroepiandrosterone sulfate with obesity. Am J Obstet Gynecol 1992; 167 (6): 1813-8
21. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84 (1): 165-9
22. Swanson M, Sauerbrei EE, Cooperberg PL. Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound 1981 May; 9 (5): 219-22
23. Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol 1990 Feb; 32 (2): 213-20
24. Isojarvi JI, Rattya J, Myllyla VV. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446-5
25. Legro RS. Polycystic ovary syndrome: current and future treatment paradigms. Am J Obstet Gynecol 1998; 179 (6 Pt 2): 101-7